Jong Kyou Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jong Kyou Kwon has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Kang Su Cho
Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
9 shared publications - Jinhyung Jeon
Department of Urology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Republic of Korea
6 shared publications - Sungun Bang
Department of Urology, Prostate Cancer Center, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
6 shared publications - Do Kyung Kim
Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - In Ho Chang
Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea
3 shared publications - Byung Hoon Chi
Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (9) , 13934-13942
Oncologic impact of en bloc seminal vesicle excision in robot-assisted radical prostatectomy for T3b prostate cancer
Background: The oncological benefit of en bloc seminal vesicle excision (EB-SVE) in T3b prostate cancer remains unestablished. We aimed to evaluate the impact of EB-SVE on histopathological outcomes and short-term clinical results in pT3b prostate cancer, compared to conventional SVE (C-SVE). Methods: We retrospectively reviewed 351 patients who underwent robotic radical prostatectomy by a single surgeon between July 2020 and December 2024. Among them, 75 patients were identified with pT3b prostate cancer. EB-SVE involves extensive removal of tissue surrounding the seminal vesicles (SVs) without direct handling or damaging them during excision. This technique was performed in cases with a preoperative suspicion of SV invasion. Conversely, C-SVE was performed in cases without such suspicion. We compared histopathological findings and short-term clinical outcomes between the EB-SVE and C-SVE groups. Results: A total of 66 patients were eligible for analysis. EB-SVE was performed unilaterally in 16 patients and bilaterally in 23 patients, while 27 patients underwent C-SVE. Among the 132 SV units (two per patient), 94 showed cancer involvement. Peri-SV tissue invasion was more frequently observed in the EB-SVE group than in the C-SVE group (87.5% vs. 52.6%, P = 0.001). However, positive surgical margins (PSMs) in peri-SV tissue occurred in only 1 SV unit (1.8%) with EB-SVE, compared to 6 SV units (15.8%) with C-SVE ( P = 0.023). Among 33 pT3b/pN0 patients, peri-SV PSM independently predicted prostate-specific antigen persistence ( P = 0.038). Conclusions: En bloc excision of peri-SV tissue via EB-SVE may reduce peri-SV PSM rates and improve short-term oncological outcomes in pT3b prostate cancer.
- 21 May 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (9) , 13934-13942
Open AccessOncologic impact of en bloc seminal vesicle excision in robot-assisted radical prostatectomy for T3b prostate cancer
Background: The oncological benefit of en bloc seminal vesicle excision (EB-SVE) in T3b prostate cancer remains unestablished. We aimed to evaluate the impact of EB-SVE on histopathological outcomes and short-term clinical results in pT3b prostate cancer, compared to conventional SVE (C-SVE). Methods: We retrospectively reviewed 351 patients who underwent robotic radical prostatectomy by a single surgeon between July 2020 and December 2024. Among them, 75 patients were identified with pT3b prostate cancer. EB-SVE involves extensive removal of tissue surrounding the seminal vesicles (SVs) without direct handling or damaging them during excision. This technique was performed in cases with a preoperative suspicion of SV invasion. Conversely, C-SVE was performed in cases without such suspicion. We compared histopathological findings and short-term clinical outcomes between the EB-SVE and C-SVE groups. Results: A total of 66 patients were eligible for analysis. EB-SVE was performed unilaterally in 16 patients and bilaterally in 23 patients, while 27 patients underwent C-SVE. Among the 132 SV units (two per patient), 94 showed cancer involvement. Peri-SV tissue invasion was more frequently observed in the EB-SVE group than in the C-SVE group (87.5% vs. 52.6%, P = 0.001). However, positive surgical margins (PSMs) in peri-SV tissue occurred in only 1 SV unit (1.8%) with EB-SVE, compared to 6 SV units (15.8%) with C-SVE ( P = 0.023). Among 33 pT3b/pN0 patients, peri-SV PSM independently predicted prostate-specific antigen persistence ( P = 0.038). Conclusions: En bloc excision of peri-SV tissue via EB-SVE may reduce peri-SV PSM rates and improve short-term oncological outcomes in pT3b prostate cancer.
- Open Access
- 31 March 2026
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 24 (1) , 3-12
Clinical Guideline for the Use of Biodegradable Rectal Spacers During Radiotherapy for Prostate Cancer
Purpose: Radiotherapy (RT) remains a cornerstone of curative treatment for localized and locally advanced prostate cancer. However, dose escalation to improve tumor control is often constrained by the proximity of the rectum, which increases the risk of gastrointestinal (GI) and genitourinary toxicities. Biodegradable rectal spacers inserted between the prostate and rectum have emerged as an effective approach to reduce rectal radiation exposure. This guideline provides evidence-based recommendations on indications, contraindications, procedural standards, and clinical management for biodegradable rectal spacer insertion during prostate cancer RT.Materials and Methods: This guideline was developed by a multidisciplinary expert panel through a systematic review of the literature, analysis of international guidelines (National Comprehensive Cancer Network, European Association of Urology, American Society for Radiation Oncology), and expert consensus among radiation oncologists, radiologists, and urologists with clinical experience in spacer insertion. The strength of each recommendation and the level of evidence were classified according to the modified GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system.Results: Spacer insertion is conditionally recommended (Grade C, Level I) for patients receiving definitive external-beam RT without rectal invasion. It reduces the high-dose rectal irradiation volume (V70–75) by >50%, decreases acute GI toxicity, and helps maintain bowel-related quality of life. However, the benefit for late severe toxicity (grade 2 or higher) remains debated in recent meta-analyses. Contraindications include rectal invasion, anatomical inaccessibility, infection, and material hypersensitivity. Procedures should be performed under local anesthesia in a sterile environment by trained physicians. Short-course antibiotics and simulator-based training, including completion of multiple supervised cases, are advised.Conclusion: Biodegradable rectal spacer insertion is clinically validated and effective in reducing acute rectal toxicity. Although pivotal trials demonstrated a favorable procedural safety profile, real-world postmarket data include reports of rare but severe procedural complications. This guideline provides standardized recommendations tailored to Korean clinical practice while remaining consistent with international standards, emphasizing the importance of operator training and careful patient selection.
- 31 March 2026
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 24 (1) , 3-12
Open AccessClinical Guideline for the Use of Biodegradable Rectal Spacers During Radiotherapy for Prostate Cancer
Purpose: Radiotherapy (RT) remains a cornerstone of curative treatment for localized and locally advanced prostate cancer. However, dose escalation to improve tumor control is often constrained by the proximity of the rectum, which increases the risk of gastrointestinal (GI) and genitourinary toxicities. Biodegradable rectal spacers inserted between the prostate and rectum have emerged as an effective approach to reduce rectal radiation exposure. This guideline provides evidence-based recommendations on indications, contraindications, procedural standards, and clinical management for biodegradable rectal spacer insertion during prostate cancer RT.Materials and Methods: This guideline was developed by a multidisciplinary expert panel through a systematic review of the literature, analysis of international guidelines (National Comprehensive Cancer Network, European Association of Urology, American Society for Radiation Oncology), and expert consensus among radiation oncologists, radiologists, and urologists with clinical experience in spacer insertion. The strength of each recommendation and the level of evidence were classified according to the modified GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system.Results: Spacer insertion is conditionally recommended (Grade C, Level I) for patients receiving definitive external-beam RT without rectal invasion. It reduces the high-dose rectal irradiation volume (V70–75) by >50%, decreases acute GI toxicity, and helps maintain bowel-related quality of life. However, the benefit for late severe toxicity (grade 2 or higher) remains debated in recent meta-analyses. Contraindications include rectal invasion, anatomical inaccessibility, infection, and material hypersensitivity. Procedures should be performed under local anesthesia in a sterile environment by trained physicians. Short-course antibiotics and simulator-based training, including completion of multiple supervised cases, are advised.Conclusion: Biodegradable rectal spacer insertion is clinically validated and effective in reducing acute rectal toxicity. Although pivotal trials demonstrated a favorable procedural safety profile, real-world postmarket data include reports of rare but severe procedural complications. This guideline provides standardized recommendations tailored to Korean clinical practice while remaining consistent with international standards, emphasizing the importance of operator training and careful patient selection.
- Open Access
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67 (2) , 162-169
Preoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences
Bang S, et al. Investig Clin Urol. 2026 Jan;67:e15. https://doi.org/10.4111/icu.20250352
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67 (2) , 162-169
Open AccessPreoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences
Bang S, et al. Investig Clin Urol. 2026 Jan;67:e15. https://doi.org/10.4111/icu.20250352
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population
This study aimed to assess the risk of secondary bladder and colorectal cancers following radiotherapy for prostate cancer using a nationwide nested case-control design based on Korea's Health Insurance Review and Assessment database. We conducted a nationwide nested case-control study using database, including men newly diagnosed with prostate cancer between 2011 and 2020. Patients were classified into radiotherapy and non-radiotherapy groups and matched 1:1 based on age, comorbidity index, and follow-up duration. Conditional logistic regression was used to assess the association between radiotherapy and secondary bladder and colorectal cancer incidences. In the crude cohort, radiotherapy was not significantly associated with secondary bladder or colorectal cancer. Kaplan-Meier analysis showed no significant differences in the cumulative incidence between radiotherapy and non-radiotherapy groups. However, nested case-control analysis revealed a significantly increased risk of secondary bladder cancer in the radiotherapy group (adjusted hazard ratio, 1.38; 95% confidence interval, 1.02 to 1.86), while no association was found for colorectal cancer (adjusted hazard ratio, 0.96; 95% confidence interval, 0.72 to 1.27). Radiotherapy was linked to an increased bladder cancer risk but not colorectal cancer risk, underscoring the need for targeted long-term surveillance.
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44
Open AccessEffects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population
This study aimed to assess the risk of secondary bladder and colorectal cancers following radiotherapy for prostate cancer using a nationwide nested case-control design based on Korea's Health Insurance Review and Assessment database. We conducted a nationwide nested case-control study using database, including men newly diagnosed with prostate cancer between 2011 and 2020. Patients were classified into radiotherapy and non-radiotherapy groups and matched 1:1 based on age, comorbidity index, and follow-up duration. Conditional logistic regression was used to assess the association between radiotherapy and secondary bladder and colorectal cancer incidences. In the crude cohort, radiotherapy was not significantly associated with secondary bladder or colorectal cancer. Kaplan-Meier analysis showed no significant differences in the cumulative incidence between radiotherapy and non-radiotherapy groups. However, nested case-control analysis revealed a significantly increased risk of secondary bladder cancer in the radiotherapy group (adjusted hazard ratio, 1.38; 95% confidence interval, 1.02 to 1.86), while no association was found for colorectal cancer (adjusted hazard ratio, 0.96; 95% confidence interval, 0.72 to 1.27). Radiotherapy was linked to an increased bladder cancer risk but not colorectal cancer risk, underscoring the need for targeted long-term surveillance.
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (2) , 301-321
Association of Perirectal Hydrogel Spacer Placement with Clinical Outcomes in Patients with Prostate Cancer Undergoing Radiotherapy: A Systematic Review and Meta-Analysis
To assess the relationship between perirectal hydrogel spacer placement and the clinical outcomes in men undergoing radiotherapy (RT) for prostate cancer. An extensive literature review was conducted using the PubMed/Medline, Embase, Cochrane Library, and Web of Science databases, encompassing studies published through June 2024. Group comparisons were performed using the weighted mean difference for continuous variables and the risk ratio for dichotomous measures. The primary endpoint was to compare rectal radiation doses with or without a perirectal spacer. Secondary outcomes included gastrointestinal (GI) and genitourinary (GU) toxicities (acute/late and any/grade ≥2, with subgroup analyses for hypofractionated RT. We reviewed 35 studies comprising 4,664 males. Rectal spacers effectively reduced the mean and maximum rectal radiation exposure, with reductions of 51.8% in V50 (mL) and 56.8% in V70 (mL). Furthermore, the percentage-based analysis showed reductions of 54.5% in V50 (%) and 62.2% in V70 (%). Acute GU toxicities (any grade and grade ≥2) showed no significant difference between the spacer and no-spacer groups, with no subgroup differences by fractionation. Late GU toxicities (any grade) were lower in the spacer group, while grade ≥2 toxicities showed no difference. Acute GI toxicities (any grade) were significantly reduced with spacers, particularly in hypofractionated RT, while grade ≥2 toxicities showed no difference. Late GI toxicities (any grade) were lower in the spacer group, with a stronger protective effect in hypofractionated RT. No significant difference was observed in grade ≥2 late GI toxicities. Hydrogel spacers significantly reduced rectal radiation exposure and overall GI toxicity. However, their limited impact on severe toxicity highlights the need for further research on high-risk treatments and advanced RT techniques.
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (2) , 301-321
Open AccessAssociation of Perirectal Hydrogel Spacer Placement with Clinical Outcomes in Patients with Prostate Cancer Undergoing Radiotherapy: A Systematic Review and Meta-Analysis
To assess the relationship between perirectal hydrogel spacer placement and the clinical outcomes in men undergoing radiotherapy (RT) for prostate cancer. An extensive literature review was conducted using the PubMed/Medline, Embase, Cochrane Library, and Web of Science databases, encompassing studies published through June 2024. Group comparisons were performed using the weighted mean difference for continuous variables and the risk ratio for dichotomous measures. The primary endpoint was to compare rectal radiation doses with or without a perirectal spacer. Secondary outcomes included gastrointestinal (GI) and genitourinary (GU) toxicities (acute/late and any/grade ≥2, with subgroup analyses for hypofractionated RT. We reviewed 35 studies comprising 4,664 males. Rectal spacers effectively reduced the mean and maximum rectal radiation exposure, with reductions of 51.8% in V50 (mL) and 56.8% in V70 (mL). Furthermore, the percentage-based analysis showed reductions of 54.5% in V50 (%) and 62.2% in V70 (%). Acute GU toxicities (any grade and grade ≥2) showed no significant difference between the spacer and no-spacer groups, with no subgroup differences by fractionation. Late GU toxicities (any grade) were lower in the spacer group, while grade ≥2 toxicities showed no difference. Acute GI toxicities (any grade) were significantly reduced with spacers, particularly in hypofractionated RT, while grade ≥2 toxicities showed no difference. Late GI toxicities (any grade) were lower in the spacer group, with a stronger protective effect in hypofractionated RT. No significant difference was observed in grade ≥2 late GI toxicities. Hydrogel spacers significantly reduced rectal radiation exposure and overall GI toxicity. However, their limited impact on severe toxicity highlights the need for further research on high-risk treatments and advanced RT techniques.
- Open Access
- 1 January 2025
- Published by XMLink in The World Journal of Men's Health
- Vol. 43
Systematic Measurement of Membranous Urethral Length Using a Cross-Reference System: A Study on Interrater Variability
Kwon J, et al. World J Mens Health. 2025 Sep;43:e72. https://doi.org/10.5534/wjmh.250139
- 1 January 2025
- Published by XMLink in The World Journal of Men's Health
- Vol. 43
Open AccessSystematic Measurement of Membranous Urethral Length Using a Cross-Reference System: A Study on Interrater Variability
Kwon J, et al. World J Mens Health. 2025 Sep;43:e72. https://doi.org/10.5534/wjmh.250139
- Open Access
- 30 November 2024
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 22 (3) , 228-236
Exploring the Evolving Role of Metastasectomy in Advanced Renal Cell Carcinoma
In the treatment of metastatic lesions in advanced renal cell carcinoma (RCC), no clear consensus exists regarding whether immunotherapy should be combined with surgical resection or metastasectomy. Systemic therapies have significantly improved outcomes for advanced RCC patients and extended both progression-free and overall survival. However, complete disease eradication with drug therapy alone remains rare, and this limitation has renewed interest in metastasectomy for metastatic RCC. Although robust evidence is still lacking, many researchers have suggested that aggressive surgical approaches involving metastasectomy may improve survival in selected patients by controlling the cancer burden through the resection of primary and metastatic lesions. Novel immunotherapies have transformed solid tumor treatment, prompting a reevaluation of the role of metastasectomy. Recent studies have shown promise in combining systemic therapies with metastasectomy for metastatic RCC, emphasizing the need for further research and individualized, multidisciplinary approaches.
- 30 November 2024
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 22 (3) , 228-236
Open AccessExploring the Evolving Role of Metastasectomy in Advanced Renal Cell Carcinoma
In the treatment of metastatic lesions in advanced renal cell carcinoma (RCC), no clear consensus exists regarding whether immunotherapy should be combined with surgical resection or metastasectomy. Systemic therapies have significantly improved outcomes for advanced RCC patients and extended both progression-free and overall survival. However, complete disease eradication with drug therapy alone remains rare, and this limitation has renewed interest in metastasectomy for metastatic RCC. Although robust evidence is still lacking, many researchers have suggested that aggressive surgical approaches involving metastasectomy may improve survival in selected patients by controlling the cancer burden through the resection of primary and metastatic lesions. Novel immunotherapies have transformed solid tumor treatment, prompting a reevaluation of the role of metastasectomy. Recent studies have shown promise in combining systemic therapies with metastasectomy for metastatic RCC, emphasizing the need for further research and individualized, multidisciplinary approaches.
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (5) , e36
The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
Kang HW, et al. J Korean Med Sci. 2017 Dec;33(5):e36. https://doi.org/10.3346/jkms.2018.33.e36
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (5) , e36
Open AccessThe Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer
Kang HW, et al. J Korean Med Sci. 2017 Dec;33(5):e36. https://doi.org/10.3346/jkms.2018.33.e36
- Open Access
- 30 September 2017
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 21 (3) , 220-228
Clinical Significance of Periurethral Calcification According to the Location in Men With Lower Urinary Tract Symptoms and a Small Prostate Volume
To assess the impact of periurethral calcification (PUC) according to its location on uroflowmetric parameters and urinary symptoms in patients with small prostate volume (PV). Records were obtained from a prospectively maintained database of first-visit men with lower urinary tract symptoms (LUTS). Patients whose PV was >30 mL were excluded to elucidate more clearly the impact of PUC on LUTS. A total of 539 patients were enrolled in the study. The prostatic urethra was examined by transrectal ultrasonography for PUC, and the location of PUC was divided into 3 areas (proximal, mid, and distal). The characteristics according to the location of PUC were compared using a 1-way analysis of variance test. The Total International Prostate Symptom Score (IPSS), postmicturition symptoms, and overactive bladder symptom score (OABSS) differed significantly among the groups. In the propensity score matching analysis, the proximal- and distal-PUC groups did not have a significantly different urinary flow rate or symptom score when compared to their matched control groups. However, the mid-PUC group had significantly worse urinary symptoms than its matched control group (total IPSS [P=0.001], voiding symptoms [P=0.002], storage symptoms [P=0.041], and OABSS [P=0.015]). The peak urinary flow rate was also lower in the mid-PUC group with borderline significance (P=0.082). On multivariate linear regression analysis, mid-PUC was independently associated with IPSS and OABSS (P=0.035 and P=0.011, respectively). Only mid-PUC was associated with symptom severity in men with LUTS and a small PV. Our findings suggest that mid-PUC could be a potential causal factor of LUTS, and the midportion of the prostatic urethra might play a pivotal role in the process of micturition.
- 30 September 2017
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 21 (3) , 220-228
Open AccessClinical Significance of Periurethral Calcification According to the Location in Men With Lower Urinary Tract Symptoms and a Small Prostate Volume
To assess the impact of periurethral calcification (PUC) according to its location on uroflowmetric parameters and urinary symptoms in patients with small prostate volume (PV). Records were obtained from a prospectively maintained database of first-visit men with lower urinary tract symptoms (LUTS). Patients whose PV was >30 mL were excluded to elucidate more clearly the impact of PUC on LUTS. A total of 539 patients were enrolled in the study. The prostatic urethra was examined by transrectal ultrasonography for PUC, and the location of PUC was divided into 3 areas (proximal, mid, and distal). The characteristics according to the location of PUC were compared using a 1-way analysis of variance test. The Total International Prostate Symptom Score (IPSS), postmicturition symptoms, and overactive bladder symptom score (OABSS) differed significantly among the groups. In the propensity score matching analysis, the proximal- and distal-PUC groups did not have a significantly different urinary flow rate or symptom score when compared to their matched control groups. However, the mid-PUC group had significantly worse urinary symptoms than its matched control group (total IPSS [P=0.001], voiding symptoms [P=0.002], storage symptoms [P=0.041], and OABSS [P=0.015]). The peak urinary flow rate was also lower in the mid-PUC group with borderline significance (P=0.082). On multivariate linear regression analysis, mid-PUC was independently associated with IPSS and OABSS (P=0.035 and P=0.011, respectively). Only mid-PUC was associated with symptom severity in men with LUTS and a small PV. Our findings suggest that mid-PUC could be a potential causal factor of LUTS, and the midportion of the prostatic urethra might play a pivotal role in the process of micturition.
- Open Access
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (5) , 750-756
Daily Mean Temperature Affects Urolithiasis Presentation in Seoul: a Time-series Analysis
Lee S, et al. J Korean Med Sci. 2016 May;31(5):750-756. https://doi.org/10.3346/jkms.2016.31.5.750
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (5) , 750-756
Open AccessDaily Mean Temperature Affects Urolithiasis Presentation in Seoul: a Time-series Analysis
Lee S, et al. J Korean Med Sci. 2016 May;31(5):750-756. https://doi.org/10.3346/jkms.2016.31.5.750